Molecular structure of Lestaurtinib, CAS Number: 111358-88-4
Lestaurtinib (CAS 111358-88-4)
See product citations (3)
Alternate Names:
(9S,10S,12R)-2,3,9,10,11,12-Hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3,2,1-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one; A 154475.0; CEP 701
Application:
Lestaurtinib is a JAK2, FLT3, and TrkA inhibitor
CAS Number:
111358-88-4
Molecular Weight:
439.46
Molecular Formula:
C26H21N3O4
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Lestaurtinib is a compound utilized in research focused on its ability to inhibit certain tyrosine kinases. Studies involving Lestaurtinib concentrate on its mechanism of action, which includes the inhibition of Janus kinases (JAKs) and Fms-like tyrosine kinase 3 (FLT3). This compound is of particular interest in the field of cellular signaling and oncology, as it may affect pathways that are critical in cell proliferation and survival. Research into Lestaurtinib′s effects on signal transduction pathways can provide insights into the regulation of these pathways and their role in disease. The compound is also employed in studies to understand the molecular basis of kinase selectivity and the structural requirements for the inhibition of specific kinases. Furthermore, Lestaurtinib is used in the synthesis of analogs that could potentially modulate kinase activity with greater specificity, which is important for expanding the toolkit of small molecules available for research in cell signaling and cancer.
Lestaurtinib (CAS 111358-88-4) References
- Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside. | Shabbir, M. and Stuart, R. 2010. Expert Opin Investig Drugs. 19: 427-36. PMID: 20141349
- Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma. | Iyer, R., et al. 2010. Clin Cancer Res. 16: 1478-85. PMID: 20179224
- Lestaurtinib: a multi-targeted FLT3 inhibitor. | Fathi, AT. and Levis, M. 2009. Expert Rev Hematol. 2: 17-26. PMID: 21082990
- Lestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis. | Diaz, T., et al. 2011. PLoS One. 6: e18856. PMID: 21533094
- Lestaurtinib is a potent inhibitor of anaplastic thyroid cancer cell line models. | Pinto, N., et al. 2018. PLoS One. 13: e0207152. PMID: 30419054
- FLT3 inhibitors in acute myeloid leukemia. | Wu, M., et al. 2018. J Hematol Oncol. 11: 133. PMID: 30514344
- Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia. | Zhao, J., et al. 2019. Biomark Res. 7: 19. PMID: 31528345
- FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. | Antar, AI., et al. 2020. Leukemia. 34: 682-696. PMID: 31919472
- Lestaurtinib potentiates TRAIL-induced apoptosis in glioma via CHOP-dependent DR5 induction. | Cao, Y., et al. 2020. J Cell Mol Med. 24: 7829-7840. PMID: 32441887
- FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. | Brown, PA., et al. 2021. Leukemia. 35: 1279-1290. PMID: 33623141
- Ponatinib, Lestaurtinib, and mTOR/PI3K Inhibitors Are Promising Repurposing Candidates against Entamoeba histolytica. | Kangussu-Marcolino, MM. and Singh, U. 2022. Antimicrob Agents Chemother. 66: e0120721. PMID: 34871094
- Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association. | Stemler, J., et al. 2022. Lancet Haematol. 9: e361-e373. PMID: 35483397
- Lestaurtinib Has the Potential to Inhibit the Proliferation of Hepatocellular Carcinoma Uncovered by Bioinformatics Analysis and Pharmacological Experiments. | Wu, S., et al. 2022. Front Cell Dev Biol. 10: 837428. PMID: 35646925
- BDNF and its signaling in cancer. | Malekan, M., et al. 2023. J Cancer Res Clin Oncol. 149: 2621-2636. PMID: 36173463
- Lestaurtinib induces DNA damage that is related to estrogen receptor activation. | Ooka, M., et al. 2023. Curr Res Toxicol. 4: 100102. PMID: 36619290
Inhibitor of:
1700019A02Rik, 1700019D03Rik, 1700019M22Rik, 1700019O17Rik, 1700020D12Rik, 2610024E20Rik, 2610030H06Rik, AIG1, AML-2, BC022651, BC023179, BC023882, BC025076, BC025816, BC026590, BC027231, BC030183, BC030336, BC030476, BC030867, BC031441, BC033915, BC037034, BC038925, BC046404, BC051019, BC052328, BC053749, C6orf126, CLEC-2B, Contrin, cortexin 3, CRB2, Ctdp1, EphB4, FAM164C, FIP1L1, FKBP15, Flt-3/Flk-2, FSHR, G6b_AU023871, GLIPR1L2, GPR108, IFN-γRβ, IFN-τ, JAK2, JAKMIP3, KKIAMRE, MASK-BP3, Mog1p, MRI1, NMU-25, NTN, PARP-10, PXT1, Rslcan-1, SCGF, SDCCAG3, SEMA3E, SOCS-5, SSXB1, STPG1, Tβ-15b, TEL, Trk A, Trk B, TrkA family transport protein, TTBK1, TTC36, TTC40, TXR1, USHBP1, VMAC, and ZNF845.Activator of:
γ1 Tubulin, Cyclophilin G, FLTR3, IFN-α/βRα, SDF-1, and Trk C.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Lestaurtinib, 1 mg | sc-218657 | 1 mg | $270.00 | |||
Lestaurtinib, 5 mg | sc-218657A | 5 mg | $320.00 | |||
Lestaurtinib, 10 mg | sc-218657B | 10 mg | $600.00 |